BBI Solutions has acquired Maine Biotechnology Services to become a premier provider of antibody services offering:
*Recombinant Antigen Development,
*Hybridoma Development (Including Anti-Idiotypic projects)
*Antibody Production and Purification Services
*Preliminary Assay Development
*Polyclonal Antibody Services
BBI brings over 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved, we have risen to the challenge of meeting those needs effectively.
The cornerstone of antibody and assay development at BBI is our technical team approach to project design and planning. The BBI antibody development plan focuses on the timely generation of data from large fusion screens that allow for identifying quality antibody candidates. A rigorous set of innovative and thorough screening tools are creatively developed and executed to meet dynamic customer goals with data-driven decision-making. If a project's goals change during development, BBI will use accumulated data to shift focus to meet the new goals efficiently. Our mission is to use these strategies to go beyond limited contract services and be a comprehensive partner in antibody and assay method development. BBI saves customers money and compresses timelines of the most complex projects.